Increasing Risk of CVDs to Help Salvage the Global Hypercholesterolemia Drugs Market Through 2020, Says Technavio

LONDON--()--The global hypercholesterolemia drugs market is expected to decline at a CAGR of close to 7% during the period 2016-2020, according to Technavio’s latest report.

In this report, Technavio covers the market outlook and growth prospects of the global hypercholesterolemia drugs market for 2016-2020. In order to calculate the market size, the report considers revenue generated from the sales of branded, generics, and off-label drugs used to treat hypercholesterolemia. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market, along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

“The global hypercholesterolemia drugs market is declining due to the entry of generics in the market as the marketed drugs have lost their patents. In addition, product recalls and withdrawals by the US Food and Drug Administration (FDA) are a challenge and negatively affect drug manufacturers in the market. For instance, in January 2014, Merck initiated a voluntary nationwide user-level recall of Liptruzet. In June 2015, the FDA discontinued this product from the market due to its safety issues. However, the decline is partially offset by the rising risk of CVDs. Hypercholesterolemia is among the primary causes of CVDs,” says Barath Palada, a lead analyst at Technavio for cardiovascular and metabolic disorders research.

Technavio’s research study segments the global hypercholesterolemia drugs market into the following regions:

  • Americas
  • EMEA
  • APAC

Americas: revision of the American Heart Association guidelines to help recover market

The hypercholesterolemia drugs market in the Americas is expected to decline at a CAGR of more than 7.4% during the forecast period owing to competition from the generic versions of branded drugs. This competition is resulting in the loss of billions of dollars of revenue. For instance, Crestor by AstraZeneca expired in the US in May 2016 while Lipitor's patent expired in 2011. However, the market is expected to recover due to the increase in the patient pool following the revision of the American Heart Association guidelines.

Ask for a sample of this report: http://goo.gl/DV3Ir3

EMEA: approval of Praluent in the EU to help contain the decline of the market

The hypercholesterolemia drugs market in EMEA is expected to decline at a CAGR of more than 6%. This is due to patent expiry of major branded drugs. However, the negative growth is partially offset by the approval of Praluent in the EU.

High cholesterol is a major health concern in the region. According to WHO, this region has the largest prevalence per capita of high cholesterol in the world. High LDL-C level increases the level of CVDs, which is the major cause of deaths worldwide. Although, there are numerous treatment options, including statins and other lipid lowering agents, Praluent is the only approved PCKS9 inhibitor in the EU for the treatment of hypercholesterolemia.

APAC: growing economies and demographics in developing countries to sustain the market

The hypercholesterolemia drugs market in APAC is expected to decline at a CAGR of close to 6%. Growing economies and demographics in developing countries such as China and India are expected to offer huge opportunities for the global hypercholesterolemia drugs market in the region. The innovation of novel products with better efficacy and safety are expected to create better opportunities for the market in the region. “The expected entry of cost-effective OTC drugs and the increased use of combination therapies will positively affect the market during the forecast period. However, side effects associated with the intake of lipid-lowering agents constitute a major challenge for this market,” says Barath.

The top vendors in the global hypercholesterolemia drugs market highlighted in the report are:

  • AstraZeneca
  • Merck
  • Pfizer
  • Aegerion Pharmaceuticals
  • AbbVie
  • Sanofi

Browse Related Reports:

Do you need a report on a market in a specific geographical cluster or country but can’t find what you’re looking for? Don’t worry, Technavio also takes client requests. Please contact enquiry@technavio.com with your requirements and our analysts will be happy to create a customized report just for you.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

The global hypercholesterolemia drugs market is expected to decline at a CAGR of close to 7% during the period 2016-2020, according to Technavio’s latest report.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com